Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02407002 · ClinicalTrials.gov registry record

Safety of Nitroglycerin for Field Treatment of STEMI

A clinical trial of Myocardial Infarction, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.

Completed
Registry status
940
Enrollment target
3
Study locations

NCT02407002: Completed study of Myocardial Infarction, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.

NCT02407002 is a study of Myocardial Infarction that has completed, run by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. The registered enrollment target is 940 participants, below the 4,667-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (80% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02407002, a study of Myocardial Infarction, has completed, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.

COMPLETED
Registry status
940 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to quantify the risk of hypotension due to field treatment with nitroglycerin in patients with ST-elevation myocardial infarction, particularly right ventricular infarcts, and secondarily to evaluate the benefit to pain relief..

Primary Outcome

SBP \<100mmHg

Conditions Studied

Myocardial Infarction

Study Locations (3)

California

  • Cedars Sinai Medical Center - Los Angeles
  • UCLA Ronald Reagan Medical Center - Los Angeles
  • Harbor-UCLA Medical Center - Torrance

Trial Details

FieldValue
Enrollment Target 940 participants
Start Date 2015-06
Est. Completion 2017-04-30
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

55 total trials

What the finished NCT02407002 record still lists

NCT02407002 is an observational study that tracks outcomes without assigning an intervention. The registered 940 participants enrollment target is mid-sized for trials with a published cap, below the 4,667-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (80% lower).

The record links to 1 condition, with Myocardial Infarction appearing as the primary indexed condition, and to 0 interventions.

NCT02407002 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT02407002 about?

NCT02407002 is a clinical study titled "Safety of Nitroglycerin for Field Treatment of STEMI". The purpose of this study is to quantify the risk of hypotension due to field treatment with nitroglycerin in patients with ST-elevation myocardial infarction, particularly right ventricular infarcts, and secondarily to evaluate the benefit to pain relief..

What is the current status of trial NCT02407002?

This trial is currently completed. The enrollment target is 940 participants. The study started on 2015-06. Estimated completion is 2017-04-30.

What conditions does trial NCT02407002 study?

This clinical trial studies the following conditions: Myocardial Infarction.

Who is sponsoring clinical trial NCT02407002?

This trial is sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02407002 being conducted?

This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Myocardial Infarction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02407002's enrollment target sits among peer trials

940 19th of 64 higher than 46 of 64 other Myocardial Infarction trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Myocardial Infarction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03075696 · 940 participants · Phase 1

    A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

  • NCT06855277 · 940 participants · Phase 3

    Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

  • NCT06808334 · 942 participants

    CLAiR Pivotal Study

  • NCT07190209 · 942 participants · Phase 3

    Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02407002, the US trial registry maintained by the National Library of Medicine. NCT02407002 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.